Decoding RNA modifications to revolutionize cancer and inflammation treatment. Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapeutic molecules to modify tRNA and target cancers and inflammatory diseases.
Location: Germany
Total raised: $3.51M
Investors 1
| Date | Name | Website |
| 07.07.2025 | LBBW Ventu... | lbbwvc.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.03.2026 | Pre-Seed | $3.51M | BaseLaunch... |
Mentions in press and media 5
| Date | Title | Description |
| 24.03.2026 | Umlaut.bio Secures €3 Million, Pioneers Novel Cancer and Autoimmune Therapies | Umlaut.bio secured €3 million in pre-seed funding. The biotech firm targets cancer and inflammatory diseases. It pioneers first-in-biology small molecules. These molecules inhibit tRNA modification synthesis. This novel mechanism prevents w... |
| 23.03.2026 | Umlaut.bio extends pre-seed round to EUR 3 million | Umlaut.bio is a pioneering biotech company focused on developing first-in-biology therapies targeting cancer and inflammatory diseases. Small molecules will be developed to inhibit key steps in tRNA modification synthesis, thereby preventi... |
| 17.03.2026 | German BioTech iDEL Therapeutics lands €9 million to develop cancer therapeutics platform | Dortmund-based iDEL Therapeutics announced the closing of a €9 million Seed financing, to develop a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells. The financing was led by BiomedVC with particip... |
| 20.02.2026 | Cancer and immunology player Umlaut.bio adds funding to reach ~€3 million pre-Seed total | Umlaut.bio, a German/Swiss oncology/immunology BioTech company developing tRNA-modifying small molecules, announced the extension of its pre-Seed financing to ~€3 million through the support of BaseLaunch. This addition not only helps to ac... |
| - | Umlaut.Bio | “Decoding RNA modifications to revolutionize cancer and inflammation treatment. Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapeutic molecules to modify tRNA and target cancers and inflammatory ... |